Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer

Yamazaki, Hideya; Nishiyama, Kinji; Koizumi, Masahiko; Tanaka, Eiichi; Ioka, Tatsuya; Uehara, Hiroyuki; Nakaizumi, Akihiko; Ohigashi, Hajime; Ishikawa, Osamu

doi:10.1007/s00066-007-1641-1

Cited by 29 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most studies have indicated that median survival time is less than 10 months [29,30]. Therefore, it is necessary to explore a new treatment method of PC.…”

Section: Discussionmentioning

confidence: 99%

Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery

Zhou

Chiu

Qin³

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

BackgroundMany previous studies demonstrated that cell adhesion molecules CD44v6 and integrin-β1 had been extensively investigated as potential prognostic markers of various cancers. However, data in PC are scarce.MethodsWe now investigate CD44v6 and integrin-β1 mRNA expression in PBMC by a triplex real-time RT-PCR assay and protein expression in plasma by ELISA. All specimens were collected from 54 PC patients who received the treatment of cryosurgery as well as 20 healthy individuals (control).ResultsThe mRNA and protein expression levels of CD44v6 and integrin-β1 in patients were significantly increased compared with control group (P<0.05). The high CD44v6 mRNA and protein expression were significantly correlated with clinical stage, tumor differentiation, LNM, liver metastasis and decreased median DFS (P<0.05), while the high integrin-β1 mRNA and protein expression were significantly correlated with clinical stage, LNM, liver metastasis and decreased median DFS (P<0.05). Clinical stage, LNM, liver metastasis, CD44v6 mRNA and protein expression were the independent predictors of survival in PC patients (P<0.05). Moreover, CD44v6 and integrin-β1 mRNA and protein expression levels were significantly decreased in patients in 3 months after cryosurgery (P<0.05). No significant difference was found in CD44v6 mRNA and protein expression between patients in 3 months after cryosurgery and control group (P>0.05).ConclusionCD44v6 and integrin-β1 mRNA and protein expression in blood may serve as biomarkers for the development and metastasis of PC, and as prognostic indicators for PC. They may become useful predictors in assessing outcome of PC patients after cryosurgery.Virtual slidesThe virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4035308681009006.

show abstract

“…However, most studies have indicated that median survival time is less than 10 months [29,30]. Therefore, it is necessary to explore a new treatment method of PC.…”

Section: Discussionmentioning

confidence: 99%

Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery

Zhou

Chiu

Qin³

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…Locally advanced pancreatic cancer has potentially distant metastasis; therefore, the dose of gemcitabine must be adequate for systemic therapy. Yamazaki et al [15] reported that concurrent administration of 1,000 mg/m 2 gemcitabine with a radiation field of GTV plus 1.3–2.0 cm with 50 Gy in 2 Gy fractions was safe. In contrast, McGinn et al [16] recommend against concurrent administration of 1,000 mg/m 2 gemcitabine with a radiation field of GTV plus 1 cm with 42 Gy in 2.8 Gy fractions.…”

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer

et al. 2010

View full text Add to dashboard Cite

A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma

Mamon

Niedzwiecki

Hollis

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The purpose of this study was to assess the efficacy and safety of 5-fluorouracil (5FU) and gemcitabine administered concurrently with radiation in patients with locally advanced, nonmetastatic pancreatic cancer. METHODS: Eligible patients had histologically confirmed pancreatic adenocarcinoma deemed locally unresectable without evidence of metastatic disease. In addition, all patients underwent laparoscopy or laparotomy before study entry to rule out peritoneal carcinomatosis. Patients received radiation therapy (50.4 Gy) with concurrent infusional 5FU (200 mg/m 2 5 days/week) and weekly gemcitabine (200 mg/m 2 ). After a 3-week break, patients received weekly gemcitabine at 1000 mg/m 2 for 3 of 4 weeks, for 4 cycles. The primary endpoint of the trial was the proportion of patients surviving 9 months from study entry. Secondary endpoints included objective tumor response, CA19-9 response, overall survival (OS) time to progression (TTP), and toxicity. RESULTS: Between November 2001 and October 2004, 81 patients were enrolled, 78 of whom were eligible for analysis. With a median follow-up of 55.2 months, the median OS was 12.2 months (95% confidence interval [CI], 10.9-14.9) and the median TTP was 10 months (95% CI, 6.4-12.0). An objective tumor response was seen in 19 patients (25%), and among 56 patients with an elevated CA19-9 at baseline, 29 (52%) had a sustained CA19-9 response. Overall, 41% of patients had grade 3 or greater treatmentrelated gastrointestinal adverse events. CONCLUSIONS: The combination of 5FU, gemcitabine, and radiation is well tolerated. Survival is comparable with the best results of other recent studies of 5FU and radiation or gemcitabine and radiation. Cancer 2011;117:2620-8.

show abstract

Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer

Abstract: Limited-field radiotherapy enables the safe concurrent administration of 1,000 mg/m(2) GEM.

Cited by 29 publications

References 31 publications

Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery

Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery

Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer

A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma

Contact Info

Product

Resources

About